Author:
Silva ND,Nobre D,dos Santos JN,Rezende MS,Pinheiro LHS,Almeida CAC,Schimieguel DM*
Publisher
Heighten Science Publications Corporation
Reference6 articles.
1. 1. Mueller BU, Seipel K, Pabst T. Myelodysplastic syndromes and acute myeloid leukemias in the elderly. Eur J Intern Med. 2018; 58: 28-32. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30527920
2. 2. DeZern AE, Malcovati L, Ebert BL. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. Am Soc Clin Oncol Educ Book. 2019; 39: 400-410. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31099654
3. 3. Zini G. Diagnostics and Prognostication of Myelodysplastic Syndromes. Ann Lab Med. 2017; 37: 465-474. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28840983
4. 4. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122: 3616-3627. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24030381
5. 5. Saha S, Halder S, Bhattacharya D, Banerjee D, Chakrabarti A. Fractional Precipitation of Plasma Proteome by Ammonium Sulphate: Case Studies in Leukemia and Thalassemia. J Proteomics Bioinformatics. 2012; 5.